ACIP Recommendations for Human Rabies Prevention Work Group

Sharon Frey, MD, FACP, FIDSA
Saint Louis University School of Medicine

On behalf of the
ACIP Rabies Work Group

Advisory Committee on Immunization Practices

October 25, 2018
Work Group Members

ACIP Members
Sharon Frey (chair)
José R. Romero

Liaison Representatives
AAP- Elizabeth Bennett
AAFP- James Stevermer
NACCHO- Matt Zahn
APhA- Karl Hess
NACI- Julie Emili and Rob Stirling
FDA- Paula Agger and Robin Levis
NASPHV- Katie Brown and Sally Slavinski

APHL-Michael Pentella

Additional Subject Matter Experts
Susan Moore
Deborah Briggs

CDC
Rabies Work Group leads – Jesse Blanton and Agam Rao
Division of Global Migration and Quarantine- Kristina Angelo
Immunization Safety Office – Pedro Moro
Work Group Purpose and Goals

- To provide a forum for discussion to update the 2008 and 2010 ACIP recommendations on human rabies prevention
- Members will review new any existing data and provide individual input on topics that may inform changes in recommendations
- Work group newly formed; first meeting was October 2018
Need for Updated Recommendations

- Rabies is an acute and fatal encephalomyelitis but is preventable
- > 200,000 persons in US exposed to rabies suspect animals / year
- >30,000 persons receive post-exposure prophylaxis (PEP) / year
- Rabies PEP is safe and efficacious but costs are high
- 2008: ACIP recommendations comprehensively updated; 2010: PEP schedule updated
- In interim, new data and World Health Organization (WHO) updated recommendations
Terms of Reference DRAFT

- Review the epidemiology and burden of rabies exposures and PEP administration in the United States
- Review evidence-based recommendations regarding use of rabies vaccine(s) and immunoglobulin products among various populations for topics including the pre-exposure prophylaxis schedule, route of vaccine administration, amount and location of rabies immune globulin, and timing of serologic monitoring
- Review efficacy, immunogenicity, safety, cost-effectiveness, route and location of vaccine administration, and vaccination schedules of rabies vaccine(s) for pre- and postexposure prophylaxis
Review rabies exposure risk for the general population and by occupational and recreational groups (e.g., veterinarians, laboratorians, travelers)

Evaluate the effectiveness and costs to adhere to current assessment guidelines and ACIP serological monitoring recommendations

Review evidence generated for new recommendations of the World Health Organization and identify where additional evidence generation may be necessary to inform recommendations

Identify areas in need of further research for informing future vaccine and immune globulin recommendations
Tentative Timeline (Subject to Change)

**PHASE I**
- CDC: Determine scope

**Mid 2018**

**PHASE II**
- Begin systematic reviews

**October 2018**

**PHASE III**
- Begin Work Group meetings

**June or October 2019 (?) to 2020**

**PHASE IV**
- Begin presenting to ACIP

**2020 or 2021**

**PHASE V**
- Update Guideline Recs
Acknowledgements

CDC Technical Work Group and Subject Matter Experts

Brett Petersen
Ryan Wallace
James Ellison
Emily Pieracci
Sathesh Panayampalli
Anna Mandra
Jesse Bonwitt
Erin Whitehouse
Thank you!

For more information, contact CDC
1-800-CDC-INFO (232-4636)

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.